1. In-Depth Characterization of a Pro-Antibody–Drug Conjugate by LC–MS
   Boning Liu et al, 2016, Molecular Pharmaceutics CrossRef
2. Preclinical risk assessment strategy to mitigate the T-cell dependent immunogenicity of protein biotherapeutics: State of the art, challenges and future perspectives
   Andrea Di Ianni et al, 2023, Journal of Pharmaceutical and Biomedical Analysis CrossRef
3. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
   Heather Donaghy, 2016, mAbs CrossRef
4. Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review
   Vittoria Perrotti et al, 2021, Cancers CrossRef
5. Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
   Ricarda M. Hoffmann et al, 2018, OncoImmunology CrossRef
6. CD44v6, STn & O-GD2: promising tumor associated antigens paving the way for new targeted cancer therapies
   Iris Lodewijk et al, 2023, Frontiers in Immunology CrossRef